Request to Join
has invited you to join this group
I am an endocrinologist and educator at Brigham and Women’s Hospital and Harvard Medical School in Boston. I am a core faculty in the HMS endocrine course; an advisor for HMS medical students during their clinical years; an associate program director for the endocrinology fellowship program at Brigham and Women’s Hospital; and also involved in several continuing medical education courses.
I am an endocrinologist at Virginia Mason with strong interests in general endocrinology, medical education, healthy policy, and quality improvement. I love all facets of endocrinology: the feedback loops, the evolving landscape of thyroid cancer management, the new innovations in T1 and T2DM, etc, etc, etc. I want to explore how technology can help achieve better health. I am the endocrine specialist for HIV Warmline, and enjoy teaching at every level from medical school students to CME for medical professionals.
I previously was a clinical endocrinology fellow in the Brigham and Women's Hospital/Harvard Medical School Cardiovascular Endocrinology Research Group, researching effects of stress on the nervous system; salt on auto-immunity; and genetic variations on the salt-sensitivity of blood pressure. Additionally, I completed a year of the Program for Clinical and Translational Science, the Partners Certificate Course in Health Policy, and the Harvard Business School Value-Based Healthcare Delivery course.
Dr. Clifford Rosen is the Principal Investigator for the Rosen Musculoskeletal Laboratory at MMCRI. His role in the PO1: The Causes and Consequences of Health Care Efficiency will be to work with the collaborative group at Dartmouth to move from clinical outcomes of drug interactions back to translational efforts in the mouse to understand mechanisms and implications. Dr. Rosen has more than twenty years of continuous NIH funding, first at The Jackson Laboratory and subsequently at Maine Medical Center Research Institute. The Rosen laboratory is studying mesenchymal stem cell fate with particular reference to the switch between pre-adipocytes and pre-osteoblasts. There are currently four NIH funded projects in this laboratory, focused on a central theme of lineage allocation, its biochemical determinants and its alterations in osteoporosis. An R24 on the biology of marrow adiposity is now in its 6th year at NIDDK and Dr. Rosen is the administrative PI for that four center interdisciplinary project. Dr. Rosen is also the Director of the Physiology Core of the MMCRI Stem Cell COBRE (NIGMS) and oversees whole body and cell phenotyping related to metabolic function. The Rosen laboratory has also been interested in cold induced thermogenesis and its effect on the skeleton as well as mitochondrial function in osteoblasts with an R21 on control of osteogenic bioenergetics. In this PO1 the Rosen laboratory will oversee the generation and treatment of mouse models with different combinations of drugs identified by investigators at Dartmouth, as well as understanding the cellular changes that may occur in the bone marrow and peripheral tissues. Dr. Rosen is the past president of the American Society of Bone and Mineral Research. He served as an associate editor at Journal of Clinical Endocrinology and Metabolism, senior associate editor at the Journal of Bone and Mineral Research and Aging Cell. He is currently an Associate Editor at New England Journal of Medicine and eLife. He completed membership on the NIH NIAMS Advisory Council, is a standing member of the FDA Endocrinologic and Metabolic Diseases Advisory Committee. Dr. Rosen has published 435 peer-reviewed publications.
Dr. Kashif Munir is an Assistant Professor of Medicine at the University of Maryland School of Medicine. He is Vice Chief of the Division of Endocrinology, Diabetes, and Nutrition and medical director of the University of Maryland Center for Diabetes and Endocrinology. He has a strong clinical and research interest in pituitary disorders.
Mark Molitch, M.D. is the Martha Leland Sherwin Professor of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine at the Northwestern University Feinberg School of Medicine. Prior to coming to Northwestern in 1984, Dr. Molitch was an Associate Professor at Tufts University School of Medicine in Boston, Massachusetts. Dr. Molitch earned an A.B. degree from Princeton University and an M.D. from the University of Pennsylvania. He did his housestaff training at the Hospital of the University of Pennsylvania and an Endocrine Fellowship at the UCLA-Harbor General Hospital in Torrance, California. Dr. Molitch has participated in clinical research for many years, focusing on the pathogenesis of pituitary tumors and their treatment as well as the complications of diabetes. He has also had a long-standing interest in the interaction between pituitary tumors and pregnancy. He has been involved in most of the initial trials of therapeutic agents for pituitary tumors. He served as the Principal Investigator for the Northwestern center of the Diabetes Control and Complications Trial and of the DCCT follow-up study called “Epidemiology of Diabetes and Its Complications” (EDIC) for the Northwestern Center of the ongoing Diabetes Prevention Program Observational Study (DPPOS) and for the Prevention of Early Renal Loss (PERL) Study. Dr. Molitch has been a member of the committees that wrote many current clinical guidelines used by endocrinologists, including those for Adult Growth Hormone Deficiency, Prolactinomas, Acromegaly, Pituitary Incidentalomas, Diabetes (Standards of Care), and Diabetic Nephropathy In addition to editing eight books and journal volumes, Dr. Molitch has authored or coauthored more than 450 original papers, review articles, book chapters, case reports and other publications. In 1997, Dr. Molitch was the recipient of the “Outstanding Physician Educator in the Field of Diabetes Award” by the American Diabetes Association and in 2013 was the recipient of the “Distinguished Educator Award” of The Endocrine Society and was President of the Pituitary Society in 2012-2013.